LXRX
Price
$1.58
Change
+$0.03 (+1.94%)
Updated
Oct 20 closing price
Capitalization
703.03M
15 days until earnings call
Intraday BUY SELL Signals
ZURA
Price
$4.00
Change
+$0.19 (+4.99%)
Updated
Oct 20 closing price
Capitalization
383.32M
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LXRX vs ZURA

LXRX vs ZURA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LXRX vs. ZURA commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Hold and ZURA is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LXRX with price predictions
Oct 20, 2026

LXRX's Indicator enters downward trend

The Aroon Indicator for LXRX entered a downward trend on October 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator formed such a pattern. In 205 of the 222 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for LXRX turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LXRX's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXRX advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

LXRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.028) is normal, around the industry mean (3.009). P/E Ratio (-9.875) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.570) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ZURA with price predictions
Oct 20, 2026

ZURA in +10.25% Uptrend, advancing for three consecutive days on October 14, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZURA advanced for three days, in 152 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZURA's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZURA as a result. In 48 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

The Moving Average Convergence Divergence (MACD) for ZURA just turned positive on October 07, 2026. Looking at past instances where ZURA's MACD turned positive, the stock continued to rise in 35 of 60 cases over the following month. The odds of a continued upward trend are 58%.

Bearish Trend Analysis

The 10-day moving average for ZURA crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

The 50-day moving average for ZURA moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ZURA broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ZURA entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.945) is normal, around the industry mean (3.009). P/E Ratio (-3.571) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ZURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
LXRX: Fundamental Ratings
LXRX
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LXRXZURA
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
68%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
59%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
47%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (LXRX: $1.58 vs. ZURA: $4.00)
Brand notoriety: LXRX and ZURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 53% vs. ZURA: 111%
Market capitalization -- LXRX: $703.03M vs. ZURA: $383.32M
LXRX [@Biotechnology] is valued at $703.03M. ZURA’s [@Biotechnology] market capitalization is $383.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 2 FA rating(s) are green while ZURA’s FA Score has 2 green FA rating(s).

  • LXRX’s FA Score: 2 green, 3 red.
  • ZURA’s FA Score: 2 green, 3 red.
According to our system of comparison, ZURA is a better buy in the long-term than LXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 4 TA indicator(s) are bullish while ZURA’s TA Score has 4 bullish TA indicator(s).

  • LXRX’s TA Score: 4 bullish, 3 bearish.
  • ZURA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than ZURA.

Price Growth

LXRX (@Biotechnology) experienced а -1.86% price change this week, while ZURA (@Biotechnology) price change was -5.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

LXRX is expected to report earnings on Nov 05, 2026.

ZURA is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LXRX
Daily Signal:
Gain/Loss:
ZURA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLRO1.890.17
+9.88%
ClearOne Inc
PHAT7.310.30
+4.28%
Phathom Pharmaceuticals
KNF51.181.60
+3.23%
Knife River Corp
ASND234.334.38
+1.90%
Ascendis Pharma A/S
STXS1.00-0.01
-1.16%
Stereotaxis

ZURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZURA has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ZURA jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZURA
1D Price
Change %
ZURA100%
+4.99%
VIR - ZURA
44%
Loosely correlated
+5.19%
RCUS - ZURA
42%
Loosely correlated
+7.27%
TNXP - ZURA
41%
Loosely correlated
+0.87%
FDMT - ZURA
39%
Loosely correlated
+6.59%
LXRX - ZURA
39%
Loosely correlated
+1.94%
More